Insider Selling: Raptor Pharmaceutical Corp. Director Unloads 5,000 Shares of Stock (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Vijay Samant sold 5,000 shares of the stock on the open market in a transaction dated Monday, October 7th. The stock was sold at an average price of $14.76, for a total transaction of $73,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on RPTP shares. Analysts at Oppenheimer downgraded shares of Raptor Pharmaceutical Corp. from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, September 25th. They noted that the move was a valuation call. Separately, analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. from $12.00 to $14.00 in a research note to investors on Friday, August 9th. Finally, analysts at JMP Securities raised their price target on shares of Raptor Pharmaceutical Corp. from $13.00 to $15.00 in a research note to investors on Friday, August 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $12.17.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded down 0.22% during mid-day trading on Wednesday, hitting $13.61. 789,484 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 52 week low of $4.35 and a 52 week high of $15.29. The stock’s 50-day moving average is $14.10 and its 200-day moving average is $9.53. The company’s market cap is $811.9 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, August 8th. The company reported ($0.30) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.30). Analysts expect that Raptor Pharmaceutical Corp. will post $-1.23 EPS for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.